The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrating aggressive variant prostate cancer–associated tumor suppressor genes (AVPC-TSG) status to refine prognosis and predict androgen-receptor pathway inhibitors (ARPI) response in metastatic hormone-sensitive prostate cancer (mHSPC).
 
Martino Pedrani
No Relationships to Disclose
 
Giuseppe Salfi
No Relationships to Disclose
 
Sara Merler
No Relationships to Disclose
 
Irene Testi
No Relationships to Disclose
 
Chiara Agrippina Clerici
No Relationships to Disclose
 
Luis Castelo-Branco
No Relationships to Disclose
 
Luigi Tortola
No Relationships to Disclose
 
Fabio Turco
Travel, Accommodations, Expenses - Bayer
 
Ursula Vogl
Consulting or Advisory Role - Pfizer, Novartis AAA, MSD, BMS, Merck, Eisei, Janssen-Cielag, Astellas, Sanofi, Roche, Ipsen
Speakers' Bureau - Pfizer, Novartis, MSD, BMS, Merck, Eisei, Janssen-Cielag, Astellas, Sanofi, Roche, Bayer, Healthbook, S. Grasso Consulting, SAMO
Research Funding - Fond’Action
Other Relationship - SAMO, OeGHO, Kantonsspital Aarau, Inselspital Bern, Kantonsspital Chur, Healthbook, S. Grasso Consulting
 
Jean-Philippe Theurillat
No Relationships to Disclose
 
Silke Gillessen
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); InnoMedica (Inst); Ipsen (Inst); Macrogenics (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); PeerVoice (Inst); Pfizer (Inst)
Speakers' Bureau - AdMeTech Foundation (Inst); ASCO GU (Inst); Avalere Health (Inst); EPG Health (Inst); ESMO; German-speaking European School of Oncology (DESO); Intellisphere (Inst); Meister ConCept GmbH (Inst); Schweizerische Gesellschaft für Medizinische Onkologie; Silvia Grasso Consulting (Inst); Swiss Group for Clinical Cancer Research (SAKK); Swiss Group for Clinical Cancer Research (SAKK) (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Gilead Sciences; Intellisphere
 
Ricardo Pereira Mestre
No Relationships to Disclose